In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

2 Similarly, the combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) resulted in an ORR of 54% and a median PFS of 17.4 months. 3 “In terms of overall survival [OS], we are also seeing a ...

Great. So my name is Mohit Bansal, and thank you for the post lunch session. So we will try to keep it exciting, just for the post lunch session. But thank you very much team Regeneron for joining us ...

Drugmaker Eli Lilly said Tuesday it will sell single-use vials of its weight-loss drug Zepbound at a fraction of the price of its pens, amid skyrocketing demand among Americans for anti-obesity ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Eli Lilly has released a new vial version of its blockbuster weight-loss drug Zepbound for about half the ...

Share on Pinterest Eli Lilly announced that single-dose vials of the weight-loss drug Zepbound will be sold at a discount price of 50% or more. Sascha Lotz/picture alliance via Getty Images The ...

Starter doses of the weight-loss drug Zepbound are now available in single-dose vials, drug manufacturer Eli Lilly announced Tuesday, a move the company says will “significantly” expand ...

Aug 27 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Tuesday it has begun selling vials of the lowest starter dose of its popular weight-loss drug Zepbound in the United States for $399 for ...

Eli Lilly & Co. is now selling vials of its blockbuster weight-loss drug Zepbound to patients for as little as $399 a month as it works to overcome supply shortages of wildly popular shots.

Eli Lilly & Co. LLY said Tuesday that patients can now access 2.5- and 5-milligram single-dose vials of its weight-loss treatment Zepbound with an on-label prescription at a discount of at least ...